Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

←Back to companies

ERD · NZX

EROAD (ERD)

Technology / Transport software•Covered: FY23 - FY26•6 published briefings

EROAD is an NZX-listed technology / transport software company with FY23 - FY26 of published result briefings.

Latest briefing

FY26 · Released 25 May 2026

$161m loss on North America impairment as EBITDA fell 35%

The headline loss is non-cash but underlying EBITDA fell from $59.6m to $39.0m and free cash flow dropped to $0.1m as capex nearly doubled.

Market data

As at close
Close price
NZD 1.06
Market cap
$199.4m
Dividend yield
0%

as at close, 15 June 2026. Source: yfinance.

Sections⌄
  1. Snapshot
  2. Valuation
  3. Chat
  4. Longitudinal View
  5. Follow-through
  6. Archive
  7. Related Insights
  1. Snapshot
  2. Valuation
  3. Chat
  4. Longitudinal View
  5. Follow-through
  6. Archive
  7. Related Insights

Snapshot

Latest metrics

FY26, released 25 May 2026

← Swipe to view more
ERD latest metrics
MetricValueChange
Revenue$195.2m↑ +0.4%
EBITDA$0m—
NPAT$0m—
Operating cash flow$30.3m↓ -29.9%
Net debt$16m↑ +35.6%
ROE %-93.5%Outside range lowOutside range low roe. -93.5%; 3-period range -1.2% to 0.4%. ROE: -93.5%, below normal range; 3-period mean -0.3%, range -1.2%-0.4%.↓ -93.9pp
PBT$0m—
FCF pre-lease$0.1m↓ -99.4%
FCF post-lease$0m—
Debtor days47↓ -1.2%

Source: latest published briefing (FY26, released 25 May 2026). Change compares against the prior equivalent period: FY25, released 26 May 2025.

Valuation

Valuation

A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.

Prices as at close, 15 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$199.4m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

0.00

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not meaningful when recent EBITDA is negative.

P/FCF

1,993.73x

i

Market cap compared with recent free cash flow.

P/B

Not available

i

Not available for this company right now.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Price history

Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.

Share price

Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.

↗
Loading chart...

Chat

Ask about ERD

Ask follow-up questions about EROAD's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about ERD

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Longitudinal view

Performance over time

The latest period is shown first.

← Swipe to view more
ERD metric history
MetricFY2612 MONTHS25 May 2026HY266 MONTHS21 November 2025FY2512 MONTHS26 May 2025FY2412 MONTHS23 May 2024HY246 MONTHS29 November 2023FY2312 MONTHS24 May 2023Trend
Revenue$195.2m$99.1m$194.4m$182m$89m$0.18m
Chart
Revenue growth %0.4%Outside range lowOutside range low revenue growth. 0.4%; 3-period range 4.1% to 52.2%. Revenue growth: 0.4%, below normal range; 3-period mean 21.0%, range 4.1%-52.2%.3.3%6.8%4.1%4.7%52.2%Outside range highOutside range high revenue growth. 52.2%; 3-period range 0.4% to 6.8%. Revenue growth: 52.2%, above normal range; 3-period mean 3.8%, range 0.4%-6.8%.
Chart
  • FY26 Revenue growth %: Outside range low revenue growth. 0.4%; 3-period range 4.1% to 52.2%. Revenue growth: 0.4%, below normal range; 3-period mean 21.0%, range 4.1%-52.2%.
EBITDA$0m$0m$0m$0m$0.03m$0.05m
Chart
EBITDA margin %0.0%Outside range lowOutside range low ebitda margin. 20%; 3-period range 25.8% to 30.7%. EBITDA margin: 20.0%, below normal range; 3-period mean 28.6%, range 25.8%-30.7%.0.0%0.0%Outside range highOutside range high ebitda margin. 30.7%; 3-period range 20% to 29.3%. EBITDA margin: 30.7%, above normal range; 3-period mean 25.0%, range 20.0%-29.3%.0.0%0.0%25.7%
Chart
  • FY25 EBITDA margin %: Outside range high ebitda margin. 30.7%; 3-period range 20% to 29.3%. EBITDA margin: 30.7%, above normal range; 3-period mean 25.0%, range 20.0%-29.3%.
  • FY26 EBITDA margin %: Outside range low ebitda margin. 20%; 3-period range 25.8% to 30.7%. EBITDA margin: 20.0%, below normal range; 3-period mean 28.6%, range 25.8%-30.7%.
PBT$0m$0m$0m$0m-$0m-$0.01m
Chart
NPAT$0m$0m$0m$0m$0m$0m
Chart
Operating cash flow$30.3m$25.7m$43.2m$52.9m$0.02m$24.1m
Chart
OCF / EBITDA %————80.8%n/m
Chart
  • FY23 OCF / EBITDA %: Outside range low ocf / ebitda cash conversion. 53.3%; 3-period range 72.5% to 99.2%. OCF / EBITDA cash conversion: 53.3%, below normal range; 3-period mean 83.1%, range 72.5%-99.2%.
FCF pre-lease$0.1m$5.1m$16m$20.7m$0.01m-$29.9m
Chart
FCF post-lease$0m$0m$0m$1.3m-$0m-$0.03m
Chart
ROE %-93.5%Outside range lowOutside range low roe. -93.5%; 3-period range -1.2% to 0.4%. ROE: -93.5%, below normal range; 3-period mean -0.3%, range -1.2%-0.4%.-77.2%0.4%Outside range highOutside range high roe. 0.4%; 3-period range -93.5% to -0.1%. ROE: 0.4%, above normal range; 3-period mean -31.6%, range -93.5%--0.1%.-0.1%-0.4%-1.2%
Chart
  • FY25 ROE %: Outside range high roe. 0.4%; 3-period range -93.5% to -0.1%. ROE: 0.4%, above normal range; 3-period mean -31.6%, range -93.5%--0.1%.
  • FY26 ROE %: Outside range low roe. -93.5%; 3-period range -1.2% to 0.4%. ROE: -93.5%, below normal range; 3-period mean -0.3%, range -1.2%-0.4%.
Net debt$16m$7.7m$11.8m$22.1m$36m$62.5m
Chart
Net debt / EBITDA————1,384.62x1,388.89x
Chart
  • FY23 Net debt / EBITDA: Outside range high net debt / ebitda. 1.38x; 3-period range 0.2x to 0.41x. Net debt / EBITDA: 1.38x, above normal range; 3-period mean 0.34x, range 0.20x-0.41x.
Debtor days476548Outside range highOutside range high debtor days. 48d; 3-period range 42d to 47d. Debtor days: 47.5 days, above normal range; 3-period mean 45.1 days, range 41.5 days-47.0 days.42Outside range lowOutside range low debtor days. 42d; 3-period range 47d to 48d. Debtor days: 41.5 days, below normal range; 3-period mean 47.1 days, range 46.9 days-47.5 days.7047
Chart
  • FY24 Debtor days: Outside range low debtor days. 42d; 3-period range 47d to 48d. Debtor days: 41.5 days, below normal range; 3-period mean 47.1 days, range 46.9 days-47.5 days.
  • FY25 Debtor days: Outside range high debtor days. 48d; 3-period range 42d to 47d. Debtor days: 47.5 days, above normal range; 3-period mean 45.1 days, range 41.5 days-47.0 days.
Inventory days0—41—5658
Chart
Total assets$308.8m$316.7m$460.3m$433.5m$0.43m$0.4m
Chart

Reference: annolyse.ai/companies/erd

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Filing-only history charts

These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.

Revenue

Reported revenue across covered periods.

↗
Loading chart...

Revenue growth

Like-period revenue growth where comparable.

↗
Loading chart...
  • FY23 ERD FY: Outside range high revenue growth. 52.2%; 3-period range 0.4% to 6.8%. Revenue growth: 52.2%, above normal range; 3-period mean 3.8%, range 0.4%-6.8%.
  • FY26 ERD FY: Outside range low revenue growth. 0.4%; 3-period range 4.1% to 52.2%. Revenue growth: 0.4%, below normal range; 3-period mean 21.0%, range 4.1%-52.2%.

EBITDA-equivalent

Company-specific earnings measure where disclosed.

↗
Loading chart...

EBITDA margin

EBITDA-equivalent margin where revenue and earnings are source-backed.

↗
Loading chart...
  • FY25 ERD FY: Outside range high ebitda margin. 30.7%; 3-period range 20% to 29.3%. EBITDA margin: 30.7%, above normal range; 3-period mean 25.0%, range 20.0%-29.3%.
  • FY26 ERD FY: Outside range low ebitda margin. 20%; 3-period range 25.8% to 30.7%. EBITDA margin: 20.0%, below normal range; 3-period mean 28.6%, range 25.8%-30.7%.

NPAT

Statutory profit after tax.

↗
Loading chart...

Operating cash flow

Cash generated from operations.

↗
Loading chart...

Full chartable metric set

Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.

OCF / EBITDA

Cash conversion against earnings.

↗
Loading chart...

FCF pre-lease

Operating cash flow less capex before leases.

↗
Loading chart...

FCF post-lease

Free cash flow after lease payments where available.

↗
Loading chart...

ROE

Return on equity.

↗
Loading chart...
  • FY25 ERD FY: Outside range high roe. 0.4%; 3-period range -93.5% to -0.1%. ROE: 0.4%, above normal range; 3-period mean -31.6%, range -93.5%--0.1%.
  • FY26 ERD FY: Outside range low roe. -93.5%; 3-period range -1.2% to 0.4%. ROE: -93.5%, below normal range; 3-period mean -0.3%, range -1.2%-0.4%.

Net debt

Borrowings less cash; negative values indicate net cash.

↗
Loading chart...

Debtor days

Receivables days where the working-capital inputs are source-backed.

↗
Loading chart...
  • FY24 ERD FY: Outside range low debtor days. 42d; 3-period range 47d to 48d. Debtor days: 41.5 days, below normal range; 3-period mean 47.1 days, range 46.9 days-47.5 days.
  • FY25 ERD FY: Outside range high debtor days. 48d; 3-period range 42d to 47d. Debtor days: 47.5 days, above normal range; 3-period mean 45.1 days, range 41.5 days-47.0 days.

Inventory days

Inventory days where the working-capital inputs are source-backed.

↗
Loading chart...

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

↗
Loading chart...
  • FY23 ERD: Outside range low operating working-capital movement. $-7.4m; 3-period range $0m to $0m. Operating working-capital movement: NZ$-7.4m, below normal range; 0/3 prior periods had builds, and none had a working-capital release.

The setup & the reality

HY26 → FY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Current result now available

FY26 · Released 25 May 2026

$161m loss on North America impairment as EBITDA fell 35%

The headline loss is non-cash but underlying EBITDA fell from $59.6m to $39.0m and free cash flow dropped to $0.1m as capex nearly doubled.

Read latest briefing→

Historical setup

What HY26 said to watch

From EROAD posts $144.2m H1 loss on charge below EBITDA as cash flow lifts

No quantitative FY26 targets are supplied. Historical shape is roughly even: HY25 was 49.3% of FY25 revenue and 49.0% of FY25 EBITDA, so annualised HY26 revenue of about $198.2m sits near the $194.4m FY25 base. NPAT shape is uninformative this period because the impairment-style charge dwarfs any normal H1/H2 split.

The release supports a read of mid-single-digit top-line growth and stable EBITDA margins; it does not support a clean read on full-year profit until the nature and recurrence of the below-EBITDA charge are clarified.

Open questions

Open questions from HY26

  • What is the nature, magnitude, and segment location of the charge that drove PBT from -$0.1m to -$136.6m while EBITDA was broadly flat?
  • Why did total equity fall by approximately $125m, and which asset categories — goodwill, intangibles, capitalised development, hardware — were written down?
  • Is the charge a one-off impairment or signal of recurring carrying-value pressure, particularly in North America where segment margin slipped to 23.4% from 25.7%?
  • How does management intend to use the de-leveraged balance sheet — organic ANZ investment, M&A, or capital return?
  • Will the step-up in capex intensity to 12.5% of revenue persist, and what return profile underwrites it?

This briefing cannot assess the composition of the below-EBITDA charge because the supplied excerpts do not disclose its line-item make-up.

Archive

Briefing archive

Every published Annolyse briefing for this company appears here in reverse chronological order.

FY26 · Released 25 May 2026

$161m loss on North America impairment as EBITDA fell 35%

The headline loss is non-cash but underlying EBITDA fell from $59.6m to $39.0m and free cash flow dropped to $0.1m as capex nearly doubled.

Read briefing→

HY26 · Released 21 November 2025

EROAD posts $144.2m H1 loss on charge below EBITDA as cash flow lifts

Revenue grew 3.3% and free cash flow rose to $5.1m, but a non-cash charge well below EBITDA drove a $144.2m loss and cut equity by roughly $125m.

Read briefing→

FY25 · Released 26 May 2025

FCF rose to $16.0m but operating cash conversion fell to 72.5%

Capex fell 58.4% as the 4G program rolled off, but OCF/EBITDA dropped from 99.2% to 72.5% even as EBITDA grew to $59.6m.

Read briefing→

FY24 · Released 23 May 2024

FCF turned positive and net debt fell $40.4m, but PBT loss widened 37.3%

Operating cash flow more than doubled to $52.9m and leverage halved, yet the loss before tax deepened despite EBITDA expanding to $53.3m.

Read briefing→

HY24 · Released 29 November 2023

Normalised revenue up 13%, EBITDA up 23.8% as net debt/EBITDA falls to 1.4x

Reported revenue growth of 4.7% understates the underlying 13% pace because HY23 carried a $7.0m one-off Coretex acquisition accounting credit.

Read briefing→

FY23 · Released 24 May 2023

Coretex full-year lift drove 52% revenue growth as net debt jumped to $62.5m

FY23 hit guidance but cash conversion fell to 53.3% and receivable days nearly doubled to 47.0 while net debt rose from $18.2m.

Read briefing→

Related insights

Compare this company

The latest ERD metrics also appear in these cross-company views.

Insight

Earnings quality and statutory distortions

This result includes a statutory earnings-quality distortion flag.

Open insight→

Insight

ROE and capital efficiency

ROE was -93.5%, -93.9pp versus the prior comparable period.

Open insight→

Insight

Cash conversion quality

This result converted 77.7% of EBITDA to operating cash flow, +5.2pp versus the prior comparable period.

Open insight→

Insight

Leverage and balance-sheet risk

Net debt / EBITDA is 0.41x, +0.21x versus the prior comparable period.

Open insight→

Get notified when ERD publishes

Get the next EROAD result briefing and five-year history updates by email.